William Flynn
Ophthalmology · San Antonio, TXNPI 1700864089
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $920 of the $1,060 with a category attached, or 86.8%. 11 manufacturers reported payments, led by AbbVie at 37.2% of the total. That places this record below the midpoint for ophthalmology clinicians in TX, where the typical reported total is $1,835.
Across 41 payments — averaging $25.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$394
- Alcon$188
- Ocular Therapeutix, Inc.$164
- Rxsight Inc$88
- Thea Pharma Inc.$70
- Johnson & Johnson Surgical Vision, Inc.$44
- plus $112 from 5 others
Across 205 payments — averaging $1877.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$267K
- AbbVie$107K
- Alcon Research LLC$4K
- Ivantis, Inc$3K
- NEW World Medical,inc.$3K
What the payments were for
- Food & beverage$92087%
- Other$14013%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 13 | $394 |
| Alcon | 9 | $188 |
| Ocular Therapeutix, Inc. | 3 | $164 |
| Rxsight Inc | 3 | $88 |
| Thea Pharma Inc. | 4 | $70 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $44 |
| Akorn, Inc. | 2 | $38 |
| NEW World Medical,inc. | 2 | $21 |
| Oyster Point Pharma, Inc. | 1 | $20 |
| Amgen | 1 | $19 |
| Rayner Intraocular Lenses Limited | 1 | $13 |
How this compares
$1,060 in reported general payments places this provider in the 35th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 190 | $123,244 |
| RhopressaNetarsudil Mesylate | 165 | $99,466 |
| RestasisCyclosporine | 52 | $70,614 |
| VyzultaLatanoprostene Bunod | 78 | $44,113 |
| CombiganBrimonidine Tartrate/Timolol | 64 | $34,553 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 121 | $22,588 |
| Prednisolone Acetate | 513 | $21,296 |
| Latanoprost | 1,657 | $20,049 |
| RocklatanNetarsudil Mesylat/Latanoprost | 41 | $17,496 |
| Brimonidine Tartrate | 373 | $16,025 |
| Travoprost | 83 | $15,649 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 38 | $14,330 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 774 | $13,756 |
| Timolol Maleate | 802 | $13,443 |
| Alphagan PBrimonidine Tartrate | 26 | $11,250 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $394 | $239,661332 claims |
| AlconSimbrinza, Azopt | $188 | $20,15254 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in San Antonio
- Michael SingerSan Antonio$1.8M
- Gregory ParkhurstSan Antonio$185K
- James LehmannSan Antonio$162K
- Oluwatosin SmithDallas$1.5M
- Charles WykoffBellaire$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.